Upload
nathaniel-powers
View
221
Download
0
Tags:
Embed Size (px)
Citation preview
A.DELENS, MEDICAL STUDENT
J.M. WEERTS,FRCS Eng, JM.DEWANDRE, D. FRANCART, C. JEHAES, B. MONAMI.
C. WHALEN, S. MARKIEWICZ
ABDOMINAL SURGERY, CHC LIEGE HOSPITAL CENTER
Cardia and gastric adenocarcinoma surgery: experience of a teaching
hospital2000 -- 2012.
Plan
IntroductionobjectivePatients and methodResultsDiscussion Conclusion
Introduction
Gastric and oesophageal adenocarcinoma incidence in Belgium during 2010: 2300 patients
Sexe ratio: 1,5 H: 1 FMean age: 72 years Overall 5-y survival:
Men: 22,3% Women: 25,3%
Introduction
Stadification
MOC
Guidelines of management:
T2 – T3/N+
Surgical resection = standard treatment for resectable gastric cancer .
D2 lymphadenectomy should be standard during gastrectomy
Splenectomy and pancreatectomy not considered standard practice if no disease infiltration
Perioperative mortality in Belgium : 5,6% (KCE report 2013)
Objective:
To evaluate:the outcome of surgical resection of gastric and cardia adenocarcinoma retrospectively.
the impact of neoadjuvant chemotherapy on survival of patients operated for cardia and gastric adenocarcinoma
Patients and methods:
Retrospective study103 consecutive patients operated in a single
institution between 2000 and 2012Including 42 women and 61 men Median age at diagnosis of 66,8 years oldTNM stage, histological stage, post-operative
morbidity and mortality, follow-up were evaluated71 patients have a follow-up of more than 5 yearsMedian follow-up??
Results
Surgery:
Oesogastric resection: N=5Total gastrectomy: N=60Partial gastrectomy: N=32Laparotomy (scopy) +bx: N=3
R1 rate: 8,7% N=9
Mortality: 5,8% ( N=6) ( Belgium : 5,6%)
Morbidity: 22,3%- Digestive: 19 - Pulmonary: 5- Cardiac: 2
N 1y
Survival 1y ( %)
N with follow up of 5yrs
minimum
Survival 5yrs (%)
global 103 76,6 71 39,5
Free of recurrence
71 39,5
men 61 72,3 46 37
women 42 80,9 25 42
Results
Belgium: 22,3% for men and 25,3% for women KCE REPORT 2013 ???
Staging N 1y
Survival 1y (%)
N 5y Survival 5y (%)
Stage IA 23 87 14 64,2
Stage IB 20 90 14 64,2
Stage II 16 81 13 53,8
Stage IIIA 13 77 8 25
Stage IIIB 10 70 5 0
Stage IV 18 44,4 15 6
location N 1y
Survival 1y (%)
N 5y Survival 5y (%)
cardia 14 42,8 11 9
gastric 89 80,8 59 42,4
Invasion depth
N 1y Survival 1y (%)
N 5y
Survival 5y (%)
pT0 3 66,6 / /
pT1 25 84 15 60
pT2 30 86,6 22 59,1
pT3 33 75,7 24 25
pT4 10 70 7 0
Nodal status
Negative 57 80,7 38 55,3
positive 43 67,4 32 21,8
N1 20 80 46,6
N2 17 64,7 0
N3 3 33,3 0
Histological type
N % survival 1 yr
N with follow up
of 5yr
% survival 5 yrs
Lauren:
diffuse 29 65,5 24 25
intestinal 71 82,6 44 47,7
WHO:
papillary 1 100 1 100
Tubular 58 82,7 34 50
Poorly differenciat
ed
11 72,7 11 8
Signet single cell
28 64,3 22 22,7
mucinous 2 100 2 50
Results
2005: Start of neoadjuvant chemotherapyPatients with advanced cancer (T2-T3, N)3 courses of 5FU-folinic acid – ciplatine
(MAGIC)
NAC Mortality: 0%NAC Morbidity: 17%response rate: 37,1%
Results
All patients with T2-T3/ N-any have been selected ( N=75)
Similar surgery morbidity and mortality
No neoadjuvant radiotherapy
D2 GastrectomyR1 rate:
Group A: N=3 Group B: N=4
Results
results
global intestinal diffuse cardia gastric
Response for all
37,1% 52%( 12/23)
10% ( 1/10)
30% ( 3/10) 40% ( 10/25)
Partial response
31,4% 44% 10% 30% 32%
Complete response
5,7 % 8% 0% 0 8%
Response to the neoadjuvant therapy:
Results
Results
Results
Cardia and gastric adenocarcinoma 503 patients:
surg alone: N=253 NAC+ surg: N=250
NAC: ECF ( epirubicin, infused fluorouracil, cisplatin): 3 courses
NAC response rate? Median follow-up?
MAGIC
5y survival:•NAC+ surg: 36%•Surg alone:23%
Results:-> no impact of NAC on perioperatives complications
-> significant impact of NAC on survival at 5 years
Hartgrink
Gastric adenocarcinoma 59 randomised patients
NAC + surg: N=29 Surg alone: N=30
Median follow-up: 83 months NAC: 5FU, doxorubicin, methotrexate NAC response rate: 32%
Hartgrink
Schuhmacher
Cardia and gastric cancer 144 randomnised patients :
NAC+ surg: N=72 Surg alone: N=72
NAC: cisplatin, folinic acid, 5FU Response rate: 36,2% ( 5,8% complete response) Median follow-up: 4,4 years
Median survival:•CTx + surg: 64,6 m•Surg alone: 52,53 m
2y survival:•CTx+ Surg: 72,7%•Surg alone: 69,9%
Conclusion
Our study does not demonstrate a significant impact of neoajuvant chemotherapy on survival at 5 years.
Conclusion